Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Canadian real estate investment and development company Leyad has marked its entry into the New York City (NYC) market with ...

Turner has received research funding from AstraZeneca, Pfizer, Roche/Genentech, MSD, Guardant Health, Invitae, Inivata, ...

In January, Endoquest’s system was accepted into the FDA’s Safer Technologies Program for devices expected to improve the safety of available treatment options. Participants in the program benefit ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or ...